The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Abstract
OBJECTIVE: Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia. This review evaluates evidence from preclinical and clinical studies that brain glutamatergic neurotransmission is altered in schizophrenia, may affect symptom expression, and is modulated by antipsychotic drugs. METHOD: A comprehensive review of scientific articles published over the last decade that address the role of glutamate in the pathophysiology of schizophrenia was carried out. RESULTS: Glutamatergic neurons are the major excitatory pathways linking the cortex, limbic system, and thalamus, regions that have been implicated in schizophrenia. Postmortem studies have revealed alterations in pre- and postsynaptic markers for glutamatergic neurons in several brain regions in schizophrenia. The N-methyl-D-aspartic acid (NMDA) subtype of glutamate receptor may be particularly important as blockade of this receptor by the dissociative anesthetics reproduces in normal subjects the symptomatic manifestations of schizophrenia, including negative symptoms and cognitive impairments, and increases dopamine release in the mesolimbic system. Agents that indirectly enhance NMDA receptor function via the glycine modulatory site reduce negative symptoms and variably improve cognitive functioning in schizophrenic subjects receiving typical antipsychotics. CONCLUSIONS: Dysfunction of glutamatergic neurotransmission may play an important role in the pathophysiology of schizophrenia, especially of the negative symptoms and cognitive impairments associated with the disorder, and is a promising target for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A synaptic model of memory: long-term potentiation in the hippocampus
Bliss, T. V. P., & Collingridge, G. L. (1993) · Nature · doi:10.1038/361031a0 · Cited by 11,566 · cited 1×
“Long-term potentiation has been linked to memory formation (24).”
BackgroundGlutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Dopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
McDonald, J. W., & Johnston, M. V. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90011-c · Cited by 1,416
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364
Jentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314
Sensorimotor Gating and Schizophrenia: Human and Animal Model Studies
Braff, D. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810140081011 · Cited by 1,309
Carlsson, M., & Carlsson, A. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90108-m · Cited by 1,082
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Modulation of Neuronal Migration by NMDA Receptors
Komuro, H., & Rakic, P. (1993) · Science · doi:10.1126/science.8096653 · Cited by 1,041
Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia
Lahti, A. (1995) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00131-i · Cited by 921
Study of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
Kim, J. S., Kornhuber, H. H., Schmid-Burgk, W., & Holzmüller, B. (1980) · Neuroscience Letters · doi:10.1016/0304-3940(80)90178-0 · Cited by 694
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
Malhotra, M. D. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 680
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150007001 · Cited by 678
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
Schizophrenia as a Disorder of Developmentally Reduced Synaptic Connectivity
McGlashan, T. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.7.637 · Cited by 655
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
Newcomer, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00067-0 · Cited by 604
D-serine added to antipsychotics for the treatment of schizophrenia
Tsai, G., Yang, P., Chung, L.-C., Lange, N., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00279-0 · Cited by 571
Self-citationEfficacy of High-Dose Glycine in the Treatment of Enduring Negative Symptoms of Schizophrenia
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Silipo, G., & Lichtenstein, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.29 · Cited by 487
NMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 1×
“express NMDA receptor subunits 2C and 2D (NR2C and NR2D), which are more sensitive to activation by glutamate, owing to a lower threshold for Mg2+ blockade, and are more sensitive to antagonists (25, 26).”
BackgroundMoller, P., & Husby, R. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033442 · Cited by 464
Akbarian, S. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820150016002 · Cited by 456
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Verma, A., & Moghaddam, B. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-01-00373.1996 · Cited by 449
Akbarian, S., Sucher, N., Bradley, D., Tafazzoli, A., Trinh, D., Hetrick, W., Potkin, S., Sandman, C., Bunney, W., & Jones, E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-01-00019.1996 · Cited by 441
Goff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Self-citationKetamine activates psychosis and alters limbic blood flow in schizophrenia
Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · NeuroReport · doi:10.1097/00001756-199504190-00011 · Cited by 434
N -Acetylaspartate in neuropsychiatric disorders
Tsai, G., & Coyle, J. T. (1995) · Progress in Neurobiology · doi:10.1016/0301-0082(95)00014-m · Cited by 422
Self-citationVollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Glutamate receptor expression in schizophrenic brain
Meador-Woodruff, J. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00044-2 · Cited by 412
Modulation of N -methyl- d -aspartate receptor function by glycine transport
Bergeron, R., Meyer, T. M., Coyle, J. T., & Greene, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15730 · Cited by 411
Self-citationJentsch, J. D., Redmond, D. E., Elsworth, J. D., Taylor, J. R., Youngren, K. D., & Roth, R. H. (1997) · Science · doi:10.1126/science.277.5328.953 · Cited by 398
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392
Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia
Deakin, J. F. W., Slater, P., Simpson, M. D. C., Gilchrist, A. C., Skan, W. J., Royston, M. C., Reynolds, G. P., & Cross, A. J. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb07257.x · Cited by 386
Gao, X.-M., Sakai, K., Roberts, R. C., Conley, R. R., Dean, B., & Tamminga, C. A. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1141 · Cited by 372
Amelioration of negative symptoms in schizophrenia by glycine
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1234 · Cited by 354
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Lieberman, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00045-6 · Cited by 333
Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.
Bakshi, V. P., Swerdlow, N. R., & Geyer, M. A. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23831-9 · Cited by 329
Facilitation of glutamate receptors enhances memory.
Staubli, U., Rogers, G., & Lynch, G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.2.777 · Cited by 328
Jentsch, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00034-1 · Cited by 320
Snyder, G. L., Allen, P. B., Fienberg, A. A., Valle, C. G., Huganir, R. L., Nairn, A. C., & Greengard, P. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04480.2000 · Cited by 310
Heresco-Levy, U., Javitt, D. C., Ermilov, M., Mordel, C., Horowitz, A., & Kelly, D. (1996) · British Journal of Psychiatry · doi:10.1192/bjp.169.5.610 · Cited by 255
Antipsychotic agents antagonize non-competitiveN-methyl-d-aspartate antagonist-induced behaviors
Corbett, R., Camacho, F., Woods, A. T., Kerman, L. L., Fishkin, R. J., Brooks, K., & Dunn, R. W. (1995) · Psychopharmacology · doi:10.1007/bf02246146 · Cited by 248
Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.8.1213 · Cited by 243
Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia
Tsai, G., Goff, D. C., Chang, R. W., Flood, J., Baer, L., & Coyle, J. T. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.9.1207 · Cited by 243
Self-citationKerwin, R., Patel, S., & Meldrum, B. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90219-t · Cited by 239
Decreased hippocampal expression of a glutamate receptor gene in schizophrenia
Harrison, P. J., McLaughlin, D., & Kerwin, R. W. (1991) · The Lancet · doi:10.1016/0140-6736(91)93392-m · Cited by 238
Multiple Structural Elements Determine Subunit Specificity of Mg2+Block in NMDA Receptor Channels
Kuner, T., & Schoepfer, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-11-03549.1996 · Cited by 235
Ibrahim, H. M., Hogg, A. J., Healy, D. J., Haroutunian, V., Davis, K. L., & Meador-Woodruff, J. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.11.1811 · Cited by 233
Krystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Glycine Uptake Governs Glycine Site Occupancy at NMDA Receptors of Excitatory Synapses
Berger, A. J., Dieudonné, S., & Ascher, P. (1998) · Journal of Neurophysiology · doi:10.1152/jn.1998.80.6.3336 · Cited by 229
d-Serine Added to Clozapine for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chung, L.-C., Tsai, I.-C., Tsai, C.-W., & Coyle, J. T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1822 · Cited by 227
Self-citationVollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Eastwood, S. L., McDonald, B., Burnet, P. W. J., Beckwith, J. P., Kerwin, R. W., & Harrison, P. J. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(94)00247-c · Cited by 207
Yamamoto, B., & Cooperman, M. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-07-04159.1994 · Cited by 203
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201
Smith, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00092-4 · Cited by 201
Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
Nishikawa, T., Takashima, M., & Toru, M. (1983) · Neuroscience Letters · doi:10.1016/0304-3940(83)90046-0 · Cited by 196
Bakshi, V. P., & Geyer, M. A. (1995) · Psychopharmacology · doi:10.1007/bf02246096 · Cited by 189
D-cycloserine added to clozapine for patients with schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.12.1628 · Cited by 182
Lindefors, N., Barati, S., & O'Connor, W. T. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00255-2 · Cited by 178
Goff, D. C., Henderson, D. C., Evins, A. E., & Amico, E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00367-9 · Cited by 178
Self-citationASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA
Kerwin, R. W., Patel, S., Meldrum, B. S., Czudek, C., & Reynolds, G. P. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91371-2 · Cited by 177
Functional Imaging of Memory Retrieval in Deficit vs Nondeficit Schizophrenia
Heckers, S., Goff, D., Schacter, D. L., Savage, C. R., Fischman, A. J., Alpert, N. M., & Rauch, S. L. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1117 · Cited by 174
Self-citationThe Nagging Question of the Function ofN-Acetylaspartylglutamate
Coyle, J. T. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0153 · Cited by 173
Self-citationWatson, G. B., Bolanowski, M. A., Baganoff, M. P., Deppeler, C. L., & Lanthorn, T. H. (1990) · Brain Research · doi:10.1016/0006-8993(90)90745-w · Cited by 172
Placebo-Controlled Trial of Glycine Added to Clozapine in Schizophrenia
Evins, A. E., Fitzgerald, S. M., Wine, L., Rosselli, R., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.826 · Cited by 172
Self-citationRegulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
Fitzgerald, L., Deutch, A., Gasic, G., Heinemann, S., & Nestler, E. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-03-02453.1995 · Cited by 171
Jentsch, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00004-9 · Cited by 164
Arvanov, V. L., Liang, X., Schwartz, J., Grossman, S., & Wang, R. Y. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37013-2 · Cited by 162
Seroquel restores sensorimotor gating in phencyclidine-treated rats.
Swerdlow, N. R., Bakshi, V. P., & Geyer, M. A. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21289-7 · Cited by 154
Svensson, T. H., Mathé, J. M., ANDERSSON, J. L., NOMIKOS, B. G., Hildebrand, B. E., & Marcus, M. M. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502001-00003 · Cited by 153
Staubli, U. V., Perez, Y., Xu, F. B., Rogers, G. A., Ingvar, M., Stone‐Elander, S., & LYNCH, G. S. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.23.11158 · Cited by 150
Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs
Leveque, J., Macias‐Konstantopoulos, W., Rajadhyaksha, A. M., Carlson, R. R., Barczak, A. K., Kang, S., Li, X., Coyle, J. T., Huganir, R. L., Heckers, S., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04011.2000 · Cited by 148
Self-citationEffect of Phencyclidine in Chronic Schizophrenics
Itil, T. M., Keskiner, A., Kiremitci, N., & Holden, J. (1967) · Canadian Psychiatric Association Journal · doi:10.1177/070674376701200217 · Cited by 148
Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant Schizophrenia
Potkin, S. G., Jin, Y., Bunney, B. G., COSTA, J. F., & Gulasekaram, B. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.1.145 · Cited by 139
Deutch, A. Y., Tam, S., Freeman, A. S., Bowers, M. B., & Roth, R. H. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90356-6 · Cited by 137
Comparison of Phencyclidine Hydrochloride (Sernyl) with Other Drugs
Cohen, B. D. (1962) · Archives of General Psychiatry · doi:10.1001/archpsyc.1962.01710230063007 · Cited by 134
Breese, C. R., Freedman, R., & Leonard, S. S. (1995) · Brain Research · doi:10.1016/0006-8993(94)01384-t · Cited by 134
Seroquel, clozapine and chlorpromazine restore sensorimotor gating in ketamine-treated rats
Swerdlow, N. R., Bakshi, V. P., Waikar, M. V., Taaid, N., & Geyer, M. A. (1998) · Psychopharmacology · doi:10.1007/s002130050741 · Cited by 131
Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation
Duncan, G. E., Leipzig, J. N., Mailman, R. B., & Lieberman, J. A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00926-3 · Cited by 131
Heckers, S., Curran, T., GOFF, D. C., Rauch, S. L., Fischman, A. J., Alpert, N. M., & Schacter, D. L. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00919-7 · Cited by 127
Self-citationTsukada, H., Harada, N., Nishiyama, S., Ohba, H., Sato, K., Fukumoto, D., & Kakiuchi, T. (2000) · Synapse · doi:10.1002/1098-2396(200008)37:2<95::aid-syn3>3.0.co;2-h · Cited by 127
Bjerkenstedt, L., Edman, G., Hagenfeldt, L., Sedvall, G., & Wiesel, F. (1985) · The British Journal of Psychiatry · doi:10.1192/bjp.147.3.276 · Cited by 127
Ishimaru, M. J., Kurumaji, A., & Toru, M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91197-5 · Cited by 115
Perry, T. L. (1982) · Neuroscience Letters · doi:10.1016/0304-3940(82)90212-9 · Cited by 112
Bakshi, V. P., & Geyer, M. A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37049-1 · Cited by 111
Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
van Berckel, B. N. M., Hijman, R., van der Linden, J. A., Westenberg, H. G. M., van Ree, J. M., & Kahn, R. S. (1996) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00311-3 · Cited by 109
Arai, A., Kessler, M., Rogers, G. A., & Lynch, G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20645-0 · Cited by 105
Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity
Farber, N. B., Foster, J., Duhan, N. L., & Olney, J. W. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(96)00024-2 · Cited by 101
Glycine Adjuvant Therapy to Conventional Neuroleptic Treatment in Schizophrenia
Rosse, R. B., Theut, S. K., Banay‐Schwartz, M., Leighton, M. P., Scarcella, E., Cohen, C. G., & Deutsch, S. I. (1989) · Clinical Neuropharmacology · doi:10.1097/00002826-198910000-00006 · Cited by 101
Glycine Therapy of Schizophrenia
Waziri, R. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90093-5 · Cited by 100
Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
Javitt, D. C., Balla, A., Sershen, H. W., & Lajtha, Á. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00237-6 · Cited by 99
Duncan, G. E., Miyamoto, S., Leipzig, J. N., & Lieberman, J. A. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39197-9 · Cited by 97
Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity
Farber, N. B., Price, M. T., Labruyere, J., Nemnich, J., Peter, H. S., Wozniak, D. F., & Olney, J. W. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90265-f · Cited by 97
Jentsch, J. D., Elsworth, J. D., Redmond, D. E., & Roth, R. H. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01769.1997 · Cited by 88
Synergistic Interactions between Ampakines and Antipsychotic Drugs
Johnson, S. A., Luu, N. T., Herbst, T., Knapp, R. J., Lutz, D., Arai, A., Rogers, G. A., & LYNCH, G. S. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38148-0 · Cited by 86
Brain region effects of clozapine on amino acid and monoamine transmission.
Yamamoto, B. K., Pehek, E. A., & Meltzer, H. Y. (1994) · PubMed · Cited by 83
Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
Tsai, G. E., van Kammen, D. P., Chen, S., Kelley, M. E., Grier, A., & Coyle, J. T. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00151-6 · Cited by 80
Self-citationSingle photon emission computed tomography in phencyclidine and related drug abuse
Hertzmann, M., Reba, R. C., & Kotlyarov, E. V. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.2.255b · Cited by 80
Johansson, C., Jackson, D. M., & Svensson, L. (1994) · Psychopharmacology · doi:10.1007/bf02247475 · Cited by 79
Simpson, M. D. C., Slater, P., Royston, M. C., & Deakin, J. F. W. (1992) · Psychiatry Research · doi:10.1016/0165-1781(92)90119-n · Cited by 78
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists
Krystal, J. H. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00102-5 · Cited by 78
Chapter 30 Nitric oxide: cellular regulation and neuronal injury
Dawson, T. M., Zhang, J., Dawson, V. L., & Snyder, S. H. (1994) · Progress in brain research · doi:10.1016/s0079-6123(08)61150-4 · Cited by 76
In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy
Kegeles, L. S., Humaran, T. J., & Mann, J. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00425-3 · Cited by 73
Riva, M. A., Tascedda, F., Lovati, E., & Racagni, G. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00175-7 · Cited by 73
Amino acid patterns in schizophrenia: Some new findings
Macciardi, F. M., Lucca, A., Catalano, M., Marino, C., Zanardi, R., & Smeraldi, E. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90136-s · Cited by 73
Wang, P. D. R., & Liang, X. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00003-7 · Cited by 68
Effects of Subchronic Clozapine and Haloperidol on Striatal Glutamatergic Synapses
Meshul, C. K., Bunker, G. L., Mason, J. N., Allen, C., & Janowsky, A. J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67051965.x · Cited by 66
Glutamate in schizophrenics and healthy controls
Gattaz, W. F., Gattaz, D., & Beckmann, H. (1982) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00343292 · Cited by 64
Jentsch, D., Dazzi, L., Chhatwal, J. P., Verrico, C. D., & Roth, R. H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00879-9 · Cited by 64
New mechanisms of excitatory transmitter neurotoxicity.
Olney, J. W. (1994) · PubMed · Cited by 63
Banerjee, S., Zuck, L., Yablonsky-Alter, E., & Lidsky, T. I. (1995) · Neuroreport · doi:10.1097/00001756-199512150-00014 · Cited by 63
LAWLOR, B. A., & Davis, K. L. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90227-q · Cited by 63
Competitive antagonism of glycine at the N-methyl-d-aspartate (NMDA) receptor
Huettner, J. E. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90004-o · Cited by 61
Schneider, J., Wade, T. V., & Lidsky, T. I. (1998) · Neuroreport · doi:10.1097/00001756-199801050-00026 · Cited by 60
Olney, J. W., & Farber, N. B. (1994) · PubMed · Cited by 60
Fletcher, E. J., & MacDonald, J. F. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90148-b · Cited by 59
Glycine Site Agonists of the NMDA Receptor: A Review
D’Souza, D. C., Charney, D. S., & Krystal, J. H. (1995) · CNS Drug Reviews · doi:10.1111/j.1527-3458.1995.tb00285.x · Cited by 59
COSTA, J., Khaled, E., Sramek, J. J., Bunney, W. E., & Potkin, S. G. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199002000-00027 · Cited by 57
Phencyclidine-induced behavioral sensitization
Xu, X., & Domino, E. F. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90165-1 · Cited by 57
Healy, D. J., & Meador‐Woodruff, J. H. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00064-8 · Cited by 55
D-Cycloserine Adjuvant Therapy to Molindone in the Treatment of Schizophrenia
Rosse, R. B., Fay-McCarthy, M., Kendrick, K., Davis, E. R., & Deutsch, S. I. (1996) · Clinical Neuropharmacology · doi:10.1097/00002826-199619050-00008 · Cited by 54
Anti-glutamatergic effects of clozapine
Lidsky, T. I., Yablonsky-Alter, E., Zuck, L., & Banerjee, S. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90370-z · Cited by 53
Lannes, B., Micheletti, G., Warter, J., Kempf, E., & Scala, G. D. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90255-r · Cited by 53
Tardive dyskinesia and substrates of energy metabolism in CSF
GOFF, D. C., Tsai, G. E., Beal, M., & Coyle, J. T. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.12.1730 · Cited by 52
Self-citationAntipsychotic drug effects on glutamatergic activity
Lidsky, T. I., Yablonsky-Alter, E., Zuck, L., et al. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00423-x · Cited by 50
Meador‐Woodruff, J. H., King, R. E., Damask, S. P., & Ka, B. (1996) · PubMed · Cited by 47
Healy, D. J., & Meador‐Woodruff, J. H. (1996) · Brain Research · doi:10.1016/0006-8993(95)01241-9 · Cited by 45
Positron emission tomography study of phencyclidine users as a possible drug model of schizophrenia.
Wu, J. C., Ms, B., & Bunney, W. E. (1991) · PubMed · Cited by 43
NMDA-Associated glycine binding site increases in schizophrenic brains
Ishimaru, M. J., Kurumaji, A., & Toru, M. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90043-y · Cited by 41
Sirviö, J., Larson, J., Quach, C. N., Rogers, G. A., & LYNCH, G. S. (1996) · Neuroscience · doi:10.1016/0306-4522(96)00170-4 · Cited by 40
The ontogeny of behavioral sensitization to phencyclidine
Scalzo, F. M. (1992) · Neurotoxicology and Teratology · doi:10.1016/0892-0362(92)90023-4 · Cited by 39
Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain
McCoy, L. A., & Richfield, E. K. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12834-2 · Cited by 33
Kerwin, R. W. (1993) · Psychological Medicine · doi:10.1017/s0033291700025319 · Cited by 30
Healy, D. J., & Meador‐Woodruff, J. H. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00204-x · Cited by 17
Glutamate Receptors in Schizophrenia and Antipsychotic Drugs
GOFF, D. C. (2000) · Handbooks of pharmacology and toxicology · doi:10.1201/9781420041774.ch8 · Cited by 12
Self-citationPositron emission tomography study of phencyclidine users
Wu, J. C., Buchsbaum, M. S., Potkin, S. G., Wolf, M. J., & Bunney, W. E. (1991) · Schizophrenia Research · doi:10.1016/0920-9964(91)90371-w · Cited by 8
Cited by
Kapur, S. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.13 · Cited by 2,813
Neuregulin 1 and Susceptibility to Schizophrenia
Stefansson, H., Petursson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342734 · Cited by 1,683
Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Metadata
- Authors
- Goff, D. C., & Coyle, J. T.
- Venue
- American Journal of Psychiatry
- Published
- 2001-09-01
- Volume
- 158
- Issue
- 9
- Pages
- 1367-1377
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2156035025
- Cited by
- 915
- References
- 147
- FWCI
- 29.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.